These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29169562)

  • 81. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
    Gottlieb AB; Gordon K; Hsu S; Elewski B; Eichenfield LF; Kircik L; Rastogi S; Pillai R; Israel R
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
    Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
    Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
    [No Abstract]   [Full Text] [Related]  

  • 83. Erythrodermic psoriasis: current and future role of biologicals.
    Stinco G; Errichetti E
    BioDrugs; 2015 Apr; 29(2):91-101. PubMed ID: 25752640
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
    Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
    J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report.
    Odorici G; Losi A; Ciardo S; Pellacani G; Conti A
    Skin Res Technol; 2018 Feb; 24(1):160-162. PubMed ID: 29067742
    [No Abstract]   [Full Text] [Related]  

  • 86. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical outcomes in patients on secukinumab (Cosentyx
    Sears AV; Szlumper C; Liu KW; Smith CH; Barker JNWN; Pink AE
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):e89-e91. PubMed ID: 30198598
    [No Abstract]   [Full Text] [Related]  

  • 88. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
    Arakawa A; Ruzicka T; Prinz JC
    JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Case of psoriatic patient who maintains long-term remission after anti-hepatitis C virus agents and ustekinumab treatment.
    Kikuchi S; Umezawa Y; Chihara M; Asahina A; Nakagawa H
    J Dermatol; 2018 Mar; 45(3):e59-e60. PubMed ID: 29388245
    [No Abstract]   [Full Text] [Related]  

  • 90. Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy.
    Shaw CA; Kole LCS; Elewski BE
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e431-e432. PubMed ID: 31220373
    [No Abstract]   [Full Text] [Related]  

  • 91. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
    Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
    Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
    [No Abstract]   [Full Text] [Related]  

  • 92. Ustekinumab: when everything else fails?
    Vitiello M; Grant A; Kerdel FA
    Int J Dermatol; 2011 Apr; 50(4):478-82. PubMed ID: 21413963
    [No Abstract]   [Full Text] [Related]  

  • 93. Response of superimposed linear psoriasis to ustekinumab: A case report.
    Weng HJ; Tsai TF
    Indian J Dermatol Venereol Leprol; 2017; 83(3):392-396. PubMed ID: 28366906
    [No Abstract]   [Full Text] [Related]  

  • 94. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
    Rigopoulos D; Gregoriou S; Makris M; Ioannides D
    Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
    Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Secukinumab for the treatment of residual psoriasis: a case series.
    Malagoli P
    J Dermatolog Treat; 2018; 29(sup1):12-13. PubMed ID: 30919723
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Unmet need for and impact of adopting immunobiological drugs for moderate to severe plaque psoriasis in a pediatric population.
    Palhano ACM; Gutierrez NM; Santos NSVD; Narikawa R; Ballalai A; Silva DLFD
    Einstein (Sao Paulo); 2024; 22():eGS0413. PubMed ID: 38865570
    [TBL] [Abstract][Full Text] [Related]  

  • 100. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.
    Talamonti M; Galluzzo M; Chimenti S; Costanzo A
    J Am Acad Dermatol; 2016 Feb; 74(2):374-5. PubMed ID: 26775778
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.